Novartis: Dermatitis trials

The registry lists 17 Dermatitis studies with Novartis as lead sponsor. 1 are open to participants now and 10 have results posted.

Phase 1 1Phase 2 5Phase 3 10Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT06947993Phase 2
• A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic DermatitisTerminatedNCT03517566Phase 2Results posted
• Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type PsoriasisCompletedNCT02074982Phase 3Results posted
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT01640951Phase 3Results posted
• Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With SecukinumabCompletedNCT01544595Phase 3Results posted
• Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT01412944Phase 3Results posted
• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose RegimensCompletedNCT01406938Phase 3Results posted
• Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type PsoriasisCompletedNCT01358578Phase 3Results posted
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisTerminatedNCT01090310Phase 3Results posted
• Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type PsoriasisCompletedNCT00805480Phase 2Results posted
• Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease ModificationTerminatedNCT00124709Phase 4Results posted
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06840392Phase 3
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Active, not recruitingNCT06799000Phase 3
• Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mgCompletedNCT01539213Phase 1
• Safety and Efficacy of DNK333 in Atopic Dermatitis PatientsCompletedNCT01033097Phase 2
• A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque PsoriasisCompletedNCT00885196Phase 2
• Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand DermatitisCompletedNCT00226707Phase 3